|
1
|
Kitchener H: Management of endometrial
cancer. Eur J Surg Oncol. 32:838–843. 2006.
|
|
2
|
Chia VM, Newcomb PA, Trentham-Dietz A and
Hampton JM: Obesity, diabetes, and other factors in relation to
survival after endometrial cancer diagnosis. Int J Gynecol Cancer.
17:441–446. 2007.
|
|
3
|
Calle EE, Rodriguez C, Walker-Thurmond K
and Thun MJ: Overweight, obesity, and mortality from cancer in a
prospectively studied cohort of U.S. adults. N Engl J Med.
348:1625–1638. 2003.
|
|
4
|
Steiner E, Plata K, Interthal C, et al:
Diabetes mellitus is a multivariate independent prognostic factor
in endometrial carcinoma: a clinicopathologic study on 313
patients. Eur J Gynaecol Oncol. 28:95–97. 2007.
|
|
5
|
Augustin LS, Dal Maso L, Franceschi S, et
al: Association between components of the insulin-like growth
factor system and endometrial cancer risk. Oncology. 67:54–59.
2004.
|
|
6
|
Schernhammer ES, Holly JM, Hunter DJ,
Pollak MN and Hankinson SE: Insulin-like growth factor-I, its
binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and
breast cancer risk in The Nurses Health Study II. Endocr Relat
Cancer. 13:583–592. 2006.
|
|
7
|
Roy RN, Gerulath AH, Cecutti A and
Bhavnani BR: Discordant expression of insulin-like growth factors
and their receptor messenger ribonucleic acids in endometrial
carcinomas relative to normal endometrium. Mol Cell Endocrinol.
153:19–27. 1999.
|
|
8
|
LeRoith D, Werner H, Beitner-Johnson D and
Roberts CT Jr: Molecular and cellular aspects of the insulin-like
growth factor I receptor. Endocr Rev. 16:143–163. 1995.
|
|
9
|
Baserga R, Hongo A, Rubini M, Prisco M and
Valentinis B: The IGF-I receptor in cell growth, transformation and
apoptosis. Biochim Biophys Acta. 1332:F105–F126. 1997.
|
|
10
|
Werner H: The molecular basis of IGF-I
receptor gene expression in human cancer. Insulin-Like Growth
Factors. LeRoith D, Zumkeller W and Baxter RC: Landes Bioscience;
Austin, TX: pp. 346–356. 2003
|
|
11
|
Navarro M and Baserga R: Limited
redundancy of survival signals from the type 1 insulin-like growth
factor receptor. Endocrinology. 142:1073–1081. 2001.
|
|
12
|
Rutanen EM: Insulin-like growth factors in
endometrial function. Gynecol Endocrinol. 12:399–406. 1998.
|
|
13
|
Oh JC, Wu W, Tortolero-Luna G, et al:
Increased plasma levels of insulin-like growth factor 2 and
insulin-like growth factor binding protein 3 are associated with
endometrial cancer risk. Cancer Epidemiol Biomarkers Prev.
13:748–752. 2004.
|
|
14
|
Pavelić J, Radaković B and Pavelić K:
Insulin-like growth factor 2 and its receptors (IGF 1R and IGF
2R/mannose 6-phosphate) in endometrial adenocarcinoma. Gynecol
Oncol. 105:727–735. 2007.
|
|
15
|
McCampbell AS, Broaddus RR, Loose DS and
Davies PJ: Overexpression of the insulin-like growth factor I
receptor and activation of the AKT pathway in hyperplastic
endometrium. Clin Cancer Res. 12:6373–6378. 2006.
|
|
16
|
Pengchong H and Tao H: Expression of
IGF-1R, VEGF-C and D2-40 and their correlation with lymph node
metastasis in endometrial adenocarcinoma. Eur J Gynaecol Oncol.
32:660–664. 2011.
|
|
17
|
Werner H and Bruchim I: The insulin-like
growth factor-I receptor as an oncogene. Arch Physiol Biochem.
115:58–71. 2009.
|
|
18
|
Cantrell LA, Zhou C, Mendivil A, Malloy
KM, Gehrig PA and Bae-Jump VL: Metformin is a potent inhibitor of
endometrial cancer cell proliferation - implications for a novel
treatment strategy. Gynecol Oncol. 116:92–98. 2010.
|
|
19
|
Rocha GZ, Dias MM, Ropelle ER, et al:
Metformin amplifies chemotherapy-induced AMPK activation and
antitumoral growth. Clin Cancer Res. 17:3993–4005. 2011.
|
|
20
|
Xie Y, Wang YL, Yu L, et al: Metformin
promotes progesterone receptor expression via inhibition of
mammalian target of rapamycin (mTOR) in endometrial cancer cells. J
Steroid Biochem Mol Biol. 126:113–120. 2011.
|
|
21
|
Parazzini F, La Vecchia C, Negri E, et al:
Diabetes and endometrial cancer: an Italian case-control study. Int
J Cancer. 81:539–542. 1999.
|
|
22
|
Grady D and Ernster VL: Endometrial
cancer. Cancer Epidemiology and Prevention. Schottenfeld D and
Fraumeni JF: 2nd edition. Oxford University Press; Oxford; pp.
1058–1089. 1996
|
|
23
|
Ouban A, Muraca P, Yeatman T and Coppola
D: Expression and distribution of insulin-like growth factor-1
receptor in human carcinomas. Hum Pathol. 34:803–808. 2003.
|
|
24
|
Petridou E, Koukoulomatis P, Alexe DM,
Voulgaris Z, Spanos E and Trichopoulos D: Endometrial cancer and
the IGF system: a case-control study in Greece. Oncology.
64:341–345. 2003.
|
|
25
|
Chen TW, Liang YN, Feng D, et al:
Metformin inhibits proliferation and promotes apoptosis of HER2
positive breast cancer cells by downregulating HSP90. J BUON.
18:51–56. 2013.
|
|
26
|
Quentin T, Steinmetz M, Poppe A and Thoms
S: Metformin differentially activates ER stress signaling pathways
without inducing apoptosis. Dis Model Mech. 5:259–269. 2012.
|
|
27
|
Olmos D, Martins AS, Jones RL, Alam S,
Scurr M and Judson IR: Targeting the Insulin-Like Growth Factor 1
Receptor in Ewing’s Sarcoma: Reality and Expectations. Sarcoma.
2011:4025082011.
|
|
28
|
Gualberto A, Hixon ML, Karp DD, et al:
Pre-treatment levels of circulating free IGF-1 identify NSCLC
patients who derive clinical benefit from figitumumab. Br J Cancer.
104:68–74. 2011.
|
|
29
|
de Bono JS, Attard G, Adjei A, et al:
Potential applications for circulating tumor cells expressing the
insulin-like growth factor-I receptor. Clin Cancer Res.
13:3611–3616. 2007.
|
|
30
|
Dowling RJ, Zakikhani M, Fantus IG, Pollak
M and Sonenberg N: Metformin inhibits mammalian target of
rapamycin-dependent translation initiation in breast cancer cells.
Cancer Res. 67:10804–10812. 2007.
|
|
31
|
Shell SA, Lyass L, Trusk PB, Pry KJ,
Wappel RL and Bacus SS: Activation of AMPK is necessary for killing
cancer cells and sparing cardiac cells. Cell Cycle. 7:1769–1775.
2008.
|
|
32
|
Vazquez-Martin A, Oliveras-Ferraros C, del
Barco S, Martin-Castillo B and Menendez JA: The antidiabetic drug
metformin: a pharmaceutical AMPK activator to overcome breast
cancer resistance to HER2 inhibitors while decreasing risk of
cardiomyopathy. Ann Oncol. 20:592–595. 2009.
|
|
33
|
Vazquez-Martin A, Oliveras-Ferraros C and
Menendez JA: The antidiabetic drug metformin suppresses HER2
(erbB-2) oncoprotein overexpression via inhibition of the mTOR
effector p70S6K1 in human breast carcinoma cells. Cell Cycle.
8:88–96. 2009.
|
|
34
|
Alimova IN, Liu B, Fan Z, et al: Metformin
inhibits breast cancer cell growth, colony formation and induces
cell cycle arrest in vitro. Cell Cycle. 8:909–915. 2009.
|
|
35
|
Liu B, Fan Z, Edgerton SM, et al:
Metformin induces unique biological and molecular responses in
triple negative breast cancer cells. Cell Cycle. 8:2031–2040.
2009.
|
|
36
|
Hadad SM, Fleming S and Thompson AM:
Targeting AMPK: a new therapeutic opportunity in breast cancer.
Crit Rev Oncol Hematol. 67:1–7. 2008.
|
|
37
|
Cazzaniga M, Bonanni B, Guerrieri-Gonzaga
A and Decensi A: Is it time to test metformin in breast cancer
clinical trials? Cancer Epidemiol Biomarkers Prev. 18:701–705.
2009.
|
|
38
|
Pollak M: Insulin and insulin-like growth
factor signalling in neoplasia. Nat Rev Cancer. 8:915–928.
2008.
|
|
39
|
Carracedo A, Baselga J and Pandolfi PP:
Deconstructing feedback-signaling networks to improve anticancer
therapy with mTORC1 inhibitors. Cell Cycle. 7:3805–3809. 2008.
|
|
40
|
Vazquez-Martin A, Oliveras-Ferraros C, Del
Barco S, Martin-Castillo B and Menendez JA: If mammalian target of
metformin indirectly is mammalian target of rapamycin, then the
insulin-like growth factor-1 receptor axis will audit the efficacy
of metformin in cancer clinical trials. J Clin Oncol. 27:e207–e209.
2009.
|
